Low VEGF expression in conceptus material and maternal serum AFP and β-hCG levels as indicators of defective angiogenesis in first-trimester miscarriages;İlk trimester gebelik kayıplarında, yetersiz anjiogenez'in göstergesi olarak konseptus materyalinde düşük VEGF ekspresyonu ve maternal serum AFP ve β-hCG düzeyleri

Journal of the Turkish German Gynecology Association

Volumn 13, Issue 2, 2012, Pages 111-117

  Kutluer, Gülşen ^a   Çiçek, Nedim Mahmut ^a   Moraloǧlu, Özlem ^a   Ertargin, Pervin ^a   Sarikaya, Esma ^a   Artar, Ishak ^a   Erdem, Özlem ^b  

^a Zekai Tahir Burak Women's Health Training and Education Hospital   (Turkey)

^b GAZI UNIVERSITY   (Turkey)

Author keywords

Abortion; AFP; Angiogenesis; Implantation; VEGF; hCG

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; VASCULOTROPIN;

ADULT; ANGIOGENESIS; ARTICLE; BLOOD SAMPLING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTROPHOBLAST; DISEASE ASSOCIATION; FEMALE; FETUS WASTAGE; FIRST TRIMESTER PREGNANCY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PATHOGENESIS; PROTEIN BLOOD LEVEL; SPONTANEOUS ABORTION; SYNCYTIOTROPHOBLAST;

EID: 84862650711     PISSN: 13090399     EISSN: 13090380     Source Type: Journal    
DOI: 10.5152/jtgga.2012.06     Document Type: Article

References (44)

1. Ribatti D. The crucial role of vascular permeability factor/vascular endothelial growth factor in angiogenesis: a historical review. Br J Haematol 2005; 128: 303-9. [CrossRef]
2. Cunningham SA, Tran TM, Arrate MP, Brock TA. Characterization of vascular endothelial cell growth factor interactions with the kinase insert domain-containing receptor tyrosine kinase. A real time kinetic study. J Biol Chem 1999; 274: 18421-7. [CrossRef]
3. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 4 1996; 380: 435-9.
4. Evans PW, Wheeler T, Anthony F, Osmond C. Maternal serum vascular endothelial growth factor during early pregnancy. Clin Sci 1997; 92: 567-71.
5. Kaloǧlu C, Bulut HE. Vascular endothelial growth factor production by rat granulated metrial gland cells and their morphological features in normal and pathological conditions. Reprod Fertil Dev 2007; 19: 341-50. [CrossRef]
6. Fasouliotis SJ, Spandorfer SD, Witkin SS, Liu HC, Roberts JE, Rosenwaks Z. Maternal serum vascular endothelial growth factor levels in early ectopic and intrauterine pregnancies after in vitro fertilization treatment. Fertil Steril 2004; 82: 309-13. [CrossRef]
7. Tsampalas M, Gridelet V, Berndt S, Foidart JM, Geenen V, Perrier d'Hauterive S. Human chorionic gonadotropin: a hormone with immunological and angiogenic properties. J Reprod Immunol 2010; 85: 93-8. [CrossRef]
8. Herr F, Baal N, Reisinger K, Lorenz A, McKinnon T, Preissner KT, et al. HCG in the regulation of placental angiogenesis. Results of an in vitro study. Placenta 2007; 21: 85-93. [CrossRef]
9. Liang OD, Korff T, Eckhardt J, Rifaat J, Baal N, Herr F, et al. Oncodevelopmental α Fetoprotein Acts as a Selective Proangiogenic Factor on Endothelial Cell from the Fetomaternal Unit. The Journal of Clinical Endocrinology & Metabolism 2004; 89(3): 1415-22. [CrossRef]
10. Zygmunt M, Herr F, Munstedt K, Lang U, Liang OD. Angiogenesis and vasculogenesis in pregnancy. Eur J Obstet Gynecol Reprod Biol 2003; 110: 10-8. [CrossRef]
11. Laitinen M, Ristimaki A, Honkasalo M, Narko K, Paavonen K, Ritvos O. Differential hormonal regulation of vascular endothelial growth factors VEGF, VEGF-B, and VEGF-C messenger ribonucleic acid levels in cultured human granulosa-luteal cells. Endocrinology 1997; 138: 4748-56. [CrossRef]
12. Johns J, Hyett J, Jauniaux E. Obstetric outcome after threatened miscarriage with and without a hematoma on ultrasound. Obstet Gynecol 2003; 102: 483-7. [CrossRef]
13. Smith GC, Shan I, Crossley JA, Atiken DA, Pell JP, Nelson SM, et al. Pregnancy-associated plasma protein A and alpha-fetoprotein and prediction of adverse perinatal outcome. Obstet Gynecol Jan 2006; 107: 161-6. [CrossRef]
14. Johns J, Jauniaux E. Threatened miscarriage as a predictor of obstetric outcome. Obstet Gynecol 2006; 107: 845-50. [CrossRef]
15. Duan L, Yan D, Zeng W, Yang X, Wei Q. Predictive power progesterone combined with beta human chorionic gonadotropin measurements in the outcome of threatened miscarriage. Arch Gynecol Obstet 2011; 283: 431-5. [CrossRef]
16. Gagnon A, Wilson RD, Audibert F, Allen VM, Blight C, Brock JA, et al. Obstetrical complications associated with abnormal maternal serum markers analytes. J Obstet Gynaecol Can 2008; 30: 918-49.
17. Doran TA, Valentine GH, Wong PY, Wielgosz G, Benzie RJ, Soltan HC, et al. Maternal serum -fetoprotein screening: report of a Canadian pilot project. CMAJ 1987; 137; 285-93.
18. Krause TG, Christens P, Wohlfahrt J, Lei U, Westergaard T, Norgaard-Pedersen B, et al. Second-trimester maternal serum alpha-fetoprotein and risk of adverse pregnancy outcome. Obstet Gynecol 2001; 97: 277-82. [CrossRef]
19. Burton BK. Outcome of pregnancy in patients with unexplained elevated or low levels of maternal serum alpha-fetoprotein. Obstet Gynecol 1988; 72: 709-13.
20. Baschat AA, Harman CR, Farid G, Chodirker BN, Evans JA. Very low second-trimester maternal serum alpha-fetoprotein: Association with high birth weight. Obstet Gynecol 2002; 99: 531-6. [CrossRef]
21. Kiran TS, Bethel J, Bhal PS. Correlation of abnormal second trimester maternal serum alpha-fetoprotein (MSAFP) levels and adverse pregnancy outcome. J Obstet Gynecol 2005; 25: 253-6.
22. Sande HA, Fagerhol M, Molnar O, Foss OP, Torjesen P. Alphafetoprotein: a marker for threatened abortion. Int J Gynaecol Obstet 1979; 16: 293-5. [CrossRef]
23. Johns J, Muttukrishna S, Lygnos M, Groome N, Jauniaux E. Maternal serum hormone concentrations for prediction of adverse outcome in threatened miscarriage. Reprod Biomed Online 2007; 15: 413-21. [CrossRef]
24. Zygmunt M, Herr F, Keller-Schoenwetter S, Munstedt K, Rao CV, Lang U, et al. Characterization of human chorionic gonadotropin as a novel angiogenic factor. J Clin Endocrinol Metab 2002; 87: 5290-6. [CrossRef]
25. Berndt S, Perrier d'Hauterive S, Blacher S, Pequeux C, Lorquet S, Munaut C, et al. Angiogenic activity of human chorionic gonadotropin through LH receptor activation on endothelial and epithelial cells of the endometrium. FASEB J 2006; 20: 2630-2. [CrossRef]
26. Evans PW, Wheeler T, Anthony FW, Osmond C. A longitudinal study of maternal serum vascular endothelial growth factor in early pregnancy. Human Reprod 1998; 13: 1057-62. [CrossRef]
27. Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 1999; 56: 794-814. [CrossRef]
28. Demir R, Kayisli UA, Seval Y, Celik-Ozenci C, Korgun ET, Demir-Weusten AY, et al. Sequential expression of VEGF and its receptors in human placental villi during very early pregnancy: differences between placental vasculogenesis and angiogenesis. Placenta 2004; 25: 560-72. [CrossRef]
29. Demir R, Kayisli UA, Cayli S, Huppertz B. Sequential steps during vasculogenesis and angiogenesis in the very early human placenta. Placenta 2006; 27: 535-9. [CrossRef]
30. Kayisli UA, Cayli S, Seval Y, Tertemiz F, Huppertz B, Demir R. Spatial and Temporal Distribution of Tie-1 and Tie-2 During very early development of the human placenta. Placenta 2006; 27: 648-59. [CrossRef]
31. Vuorela P, Carpen O, Tulppala M, Halmesmaki E. VEGF, its receptors and the tie receptors in recurrent miscarriage. Mol Hum Reprod 2000; 6: 276-82. [CrossRef]
32. Sugino N, Kashida S, Karube-Harada A, Takiguchi S, Kato H. Expression of vascular endothelial growth factor (VEGF) and its receptors in human endometrium throughout the menstrual cycle and in early pregnancy. Reproduction 2002; 123: 379-87. [CrossRef]
33. Kaufmann P, Mayhew TM, Charnock-Jones DS. Aspects of human fetoplacental vasculogenesis and angiogenesis. II. Changes during normal pregnancy. Placenta 2004; 25: 114-26. [CrossRef]
34. Muttukrishna S, Suri S, Groome NP, Jauniaux E. Relationships between TGFf{hook}À proteins and oxygen concentrations inside the first trimester human gestational sac. PLoS ONE 2008; 3: e2302. [CrossRef]
35. Plaisier M, Rodrigues S, Willems F, Koolwijk P, van Hinsbergh VW, Helmerhorst FM. Different degrees of vascularization and their relationship to the expression of vascular endothelial growth factor, placental growth factor, angiopoietins, and their receptors in firsttrimester decidual tissues. Fertil Steril 2007; 88: 176-87. [CrossRef]
36. Smith GC, Crossley JA, Aitken DA, Jenkins N, Lyall F, Cameron AD, et al. Circulating angiogenic factors in early pregnancy and the risk of preeclampsia, intrauterine growth restriction, spontaneous preterm birth, and stillbirth. Obstet Gynecol 2007; 109: 1316-24. [CrossRef]
37. Vuorela P, Hatva E, Lymboussaki A, Kaipainen A, Joukov V, Persico MG, et al. Expression of vascular endothelial growth factor and placenta growth factor in human placenta. Biol Reprod 1997; 56: 489-94. [CrossRef]
38. Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, et al. A longitudinal study of angiogenic (placental growth factor) and antiangiogenic (soluble endoglin and soluble VEGF receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small-for-gestational-age neonate. J Matern Fetal Neonatal Med 2008; 21: 9-23. [CrossRef]
39. Muttukrishna S, Swer M, Suri S, Jamil A, Calleja-Agius J, Gangooly S, et al. Soluble Flt-1 and PlGF: New Markers of Early Pregnancy Loss? PLoS ONE 2011; 6: e18041. [CrossRef]
40. Pauli SA, Tang H, Wang J, Bohlen P, Posser R, Hartman T, et al. The Vascular Endothelial Growth Factor (VEGF)/VEGF Receptor 2 Pathway Is Critical for Blood Vessel Survival in Corpora Lutea of Pregnancy in the Rodent. Endocrinology 2005; 146: 1301-11. [CrossRef]
41. Papazoǧlu D, Galazios G, Papatheodorou K, Liberis V, Papanas N, Maltezos E, et al. Vascular endothelial growth factor gene polymorphisms and idiopathic recurrent pregnancy loss. Fertil Steril 2005; 83: 959-63. [CrossRef]
42. Douglas NC, Tang H, Gomez R, Pytowski B, Hicklin DJ, Sauer CM, et al. Vascular Endothelial Growth Factor Receptor 2 (VEGFR- 2) Functions to Promote Uterine Decidual Angiogenesis during Early Pregnancy in the Mouse. Endocrinology 2009; 150: 3845-54. [CrossRef]
43. M. Differential Roles of Vascular Endothelial Growth Factor Receptor -1 and Receptor-2 in angiogenesis. J Biochem. Mol. Biol 2006; 39: 469-78. [CrossRef]
44. Chai J, Jones MK, Tarnawski AS. Serum response factor is a critical requirement for VEGF signaling in endothelial cells and VEGFinduced angiogenesis. The FASEB J 2004; 18: 1264-6.